Novartis | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Alcon AG USD 1.38B 14M 2024-12
Almirall EUR 231.69M 73.09M 2024-06
Amgen USD 5.97B 781M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Autolus Therapeutics Ltd -11358000 11.24M 2024-12
Bayer EUR 6.01B 1.13B 2024-12
Biogen USD 1.87B 44.1M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Fresenius EUR 1.42B 52M 2024-12
Fresenius Medical Care EUR 1.27B 124.43M 2024-12
Galapagos EUR -37430000 97.26M 2024-12
Genmab DKK 6.1B 837M 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.56B 57M 2024-12
GRIFOLS EUR 766.49M 39.74M 2024-12
Hikma Pharmaceutical USD 756M 82M 2024-06
J&J USD 15.41B 102M 2024-12
Lonza CHF 1.12B 276M 2024-06
Merck EUR 3.1B 45M 2024-12
Merck USD 11.92B 852M 2024-12
Novartis USD 10.23B 294M 2024-12
Novartis USD 10.24B 313M 2024-12
Novo Nordisk 60B 2.22B 2024-09
Orion EUR 267.3M 52.1M 2024-12
Pfizer USD 12.11B 718M 2024-12
Philips EUR 1.96B 43M 2024-12
Recordati EUR 385.12M 1.11M 2024-09
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 10.07B 2.1B 2024-09
UCB EUR 970M 788M 2024-06



Novartis Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.